Immunotherapy in Nonmetastatic NSCLC

Download these slides from a live CCO Webinar for an overview of the evolving immunotherapy landscape for early-stage resectable and stage III unresectable NSCLC.
person default
Jarushka Naidoo, MB BCH BAO, MHS
Format: Microsoft PowerPoint (.ppt)
File Size: 2.87 MB
Released: September 17, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Genentech, a member of the Roche Group
Helsinn Healthcare SA
Merck Sharp & Dohme Corp.

Related Content

Downloadable resource: current EGFR-targeted agents for advanced NSCLC with EGFR mutations, including exon 20 insertions, from Clinical Care Options (CCO)

Released: May 24, 2022

Downloadable resource on active research and ongoing clinical trials in EGFR-mutated NSCLC, from Clinical Care Options (CCO)

Released: May 24, 2022

Downloadable resource on best practices for molecular testing of targetable biomarkers in advanced NSCLC (May 2022), from Clinical Care Options (CCO)

Released: May 24, 2022

Clinical Care Options (CCO) commentary: Joel Neal, MD, discusses management of non-small-cell lung cancer (NSCLC) with uncommon EGFR mutations

Joel W. Neal, MD, PhD Released: May 20, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings